We use cookies to see how investors use El Fondo and make its tools, data and markets better for you. You can accept or reject; essential cookies always stay on. Privacy Policy
Trades about 54% below its sector, cheaper than its peers on earnings.
Greenyn Biotechnology Co., Ltd is an enterprise specializing in dietary supplements, dedicated to the development, production, and worldwide distribution of health-enhancing products. Their product portfolio includes a range of proprietary active ingredients. These feature notable components such as Insumate, derived from bitter melon extract; Antromax, which utilizes antrodia cinnamomea; and the Zymologist 101 Phyto fermented drink. Beyond individual ingredients, Greenyn provides an extensive selection of functional product series catering to a diverse array of health and wellness needs. These encompass solutions for youth and beauty, digestive and brain health, overall body regulation, throat care, hair care, vision support, and various lifestyle enhancement formulas. Additional ranges include joint health, general nutritional and energy supplementation, immune modulation, low-burden options, sleep assistance, body contouring, circulatory support, specific formulas for men's vitality and women's intimate health, and dedicated products for mature women. Moreover, the company extends its expertise through various services, including custom product development, Original Design Manufacturing (ODM), dosage form optimization, and application support. Established in 2012, the firm's operations are headquartered in Taichung, Taiwan.
Loading the full price history…
Run your own numbersPast performance is not a forecast.
Save 6846.TWO and get told when something moves.
Get updates
A clear, direct weekly summary.
Learn the fundamentals behind this asset.
A stock is a fraction of ownership in a real company. Buy one share and you own a piece (usually a tiny piece) of every desk, factory, contract and brand the company runs. The price moves because the market keeps revising what that whole pie is worth.
The price-to-earnings ratio is how much investors are paying for one dollar of a company's profit. A multiple, never an absolute. Always compared to something: a sector, a region, the company's own past.
Dividend yield is the annual income a stock or ETF pays out, expressed as a percentage of what you paid for it. It is the visible part of total return: the cash that lands in your account every quarter, and the lever most retail investors actually feel.
Market cap is shares times price. A simple formula that produces wildly unequal numbers: a single US tech name can be worth more than every company on a LATAM exchange combined.
